David N. Fisman

19.4k total citations · 5 hit papers
241 papers, 11.8k citations indexed

About

David N. Fisman is a scholar working on Epidemiology, Infectious Diseases and Modeling and Simulation. According to data from OpenAlex, David N. Fisman has authored 241 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Epidemiology, 75 papers in Infectious Diseases and 71 papers in Modeling and Simulation. Recurrent topics in David N. Fisman's work include COVID-19 epidemiological studies (71 papers), Influenza Virus Research Studies (50 papers) and Vaccine Coverage and Hesitancy (23 papers). David N. Fisman is often cited by papers focused on COVID-19 epidemiological studies (71 papers), Influenza Virus Research Studies (50 papers) and Vaccine Coverage and Hesitancy (23 papers). David N. Fisman collaborates with scholars based in Canada, United States and United Kingdom. David N. Fisman's co-authors include Ashleigh R. Tuite, Amy L. Greer, Galit Kleiner‐Fisman, Kevin A. Brown, Nick Daneman, Anthony E. Lang, Marc Lipsitch, Nagham Khanafer, Trisha Greenhalgh and Kimberly A. Prather and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David N. Fisman

233 papers receiving 11.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transmission Dynamics and Control of Severe Acute Respiratory Syndrome

2003 1.0k citations Marc Lipsitch, David N. Fisman et al. profile →
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes

2006 692 citations David N. Fisman et al. profile →
Ten scientific reasons in support of airborne transmission of SARS-CoV-2

2021 544 citations David N. Fisman et al. The Lancet profile →
Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection

2013 419 citations Kevin A. Brown, Nick Daneman et al. Antimicrobial Agents and Chemotherapy profile →
Antibiotic resistance increases with local temperature

2018 344 citations Derek R. MacFadden, David N. Fisman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David N. Fisman Canada	50	3.7k	3.4k	3.0k	1.4k	1.3k	241	11.8k
Jaffar A. Al‐Tawfiq Saudi Arabia	57	7.6k 2.0×	2.9k 0.9×	2.1k 0.7×	2.0k 1.4×	844 0.7×	385	13.3k
David L. Swerdlow United States	59	7.1k 1.9×	2.6k 0.8×	1.6k 0.5×	1.3k 0.9×	1.3k 1.0×	188	16.0k
Wen‐Chien Ko Taiwan	62	7.7k 2.1×	6.1k 1.8×	967 0.3×	1.9k 1.4×	1.2k 0.9×	589	23.1k
Robert Booy Australia	55	2.9k 0.8×	5.8k 1.7×	1.4k 0.5×	1.7k 1.3×	335 0.3×	317	12.5k
Tamara Pilishvili United States	34	3.1k 0.8×	6.9k 2.0×	764 0.3×	804 0.6×	876 0.7×	90	11.8k
Trish M. Perl United States	68	8.4k 2.3×	5.2k 1.5×	862 0.3×	2.5k 1.8×	1.3k 1.0×	287	24.6k
Arnaud Fontanet France	54	6.2k 1.7×	4.8k 1.4×	1.6k 0.5×	1.7k 1.3×	355 0.3×	272	12.2k
Vincent Chi‐Chung Cheng China	68	14.4k 3.9×	5.2k 1.5×	2.1k 0.7×	1.3k 0.9×	1.8k 1.4×	369	23.1k
Giovanni Rezza Italy	56	8.0k 2.2×	4.0k 1.2×	1.0k 0.3×	3.7k 2.7×	930 0.7×	394	14.2k
C. Raina MacIntyre Australia	61	4.2k 1.1×	5.6k 1.7×	2.6k 0.9×	1.3k 0.9×	287 0.2×	563	16.0k

Countries citing papers authored by David N. Fisman

Since Specialization

Citations

This map shows the geographic impact of David N. Fisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Fisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Fisman more than expected).

Fields of papers citing papers by David N. Fisman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Fisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Fisman. The network helps show where David N. Fisman may publish in the future.

Co-authorship network of co-authors of David N. Fisman

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Fisman. A scholar is included among the top collaborators of David N. Fisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Fisman. David N. Fisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Postma, Maarten J., et al.. (2025). Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs. Vaccine. 51. 126879–126879. 1 indexed citations

Fisman, David N., et al.. (2024). Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval. Vaccine. 42(25). 126134–126134.

Fisman, David N., et al.. (2024). Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America. SHILAP Revista de lepidopterología. 12(12). 331–331. 6 indexed citations

Sturrock, Shelby L., Isha Berry, Nick Daneman, et al.. (2024). Public transit mobility as a leading indicator of COVID-19 transmission in 40 cities during the first wave of the pandemic. PeerJ. 12. e17455–e17455. 2 indexed citations

Fisman, David N. & Ashleigh R. Tuite. (2022). Age-Specific Changes in Virulence Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. Clinical Infectious Diseases. 75(1). e69–e75. 11 indexed citations

Tuite, Ashleigh R., et al.. (2022). Severity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Pregnancy in Ontario: A Matched Cohort Analysis. Clinical Infectious Diseases. 76(3). e200–e206. 4 indexed citations

Tuite, Ashleigh R., et al.. (2022). Relative Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Vaccinated and Unvaccinated Individuals Hospitalized With SARS-CoV-2. Clinical Infectious Diseases. 76(3). e409–e415. 11 indexed citations

Berry, Isha, Punam Mangtani, Mahbubur Rahman, et al.. (2021). Population Health Surveillance Using Mobile Phone Surveys in Low- and Middle-Income Countries: Methodology and Sample Representativeness of a Cross-sectional Survey of Live Poultry Exposure in Bangladesh. JMIR Public Health and Surveillance. 7(11). e29020–e29020. 6 indexed citations

Brankston, Gabrielle, Eric Merkley, David N. Fisman, et al.. (2021). Quantifying contact patterns in response to COVID-19 public health measures in Canada. BMC Public Health. 21(1). 2040–2040. 20 indexed citations

10.

Saeed, Sahar, Sheila F. O’Brien, Kento T. Abe, et al.. (2021). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLoS ONE. 16(9). e0257743–e0257743. 12 indexed citations

11.

Fisman, David N., et al.. (2020). Derivation and Validation of Clinical Prediction Rules for COVID-19 Mortality in Ontario, Canada. Open Forum Infectious Diseases. 7(11). ofaa463–ofaa463. 14 indexed citations

12.

MacFadden, Derek R., Bryan Coburn, Karel Břinda, et al.. (2020). Using Genetic Distance from Archived Samples for the Prediction of Antibiotic Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy. 64(5). 8 indexed citations

13.

Guthrie, Jennifer L., David N. Fisman, & Jennifer L. Gardy. (2017). Self-rated health and reasons for non-vaccination against seasonal influenza in Canadian adults with asthma. PLoS ONE. 12(2). e0172117–e0172117. 18 indexed citations

14.

McGirr, Ashleigh & David N. Fisman. (2015). Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis. PEDIATRICS. 135(2). 331–343. 128 indexed citations

15.

Fisman, David N., GM Leung, & Marc Lipsitch. (2014). Nuanced risk assessment for emerging infectious diseases. The Lancet. 383(9913). 189–190. 19 indexed citations

16.

Ross, Stephanie, et al.. (2012). Relative risk of cervical cancer in indigenous women in Australia, Canada, New Zealand, and the United States: A systematic review and meta-analysis. Journal of Public Health Policy. 33(2). 148–164. 38 indexed citations

17.

Fisman, David N., et al.. (2012). Estimating the Value of Connections to Vice-President Cheney. The B E Journal of Economic Analysis & Policy. 13(3). 98 indexed citations

18.

Laupland, Kevin B. & David N. Fisman. (2011). Surviving Sepsis?. Canadian Journal of Infectious Diseases and Medical Microbiology. 22(4). 129–131. 1 indexed citations

19.

Andradóttir, Sigrún, David Goldsman, Kwok‐Leung Tsui, et al.. (2010). Simulation of strategies for containing pandemic influenza. Winter Simulation Conference. 2221–2229. 2 indexed citations

20.

To, Teresa, Astrid Guttmann, M. Diane Lougheed, et al.. (2010). Evidence-based performance indicators of primary care for asthma: a modified RAND Appropriateness Method. International Journal for Quality in Health Care. 22(6). 476–485. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact